GlassScriptPhysician profile
Ethnie S Jones
NPI 1972611697
$1,971,403.45
in general payments reported to CMS, 2019-2025
20 companies · $3,814 in 2025
The $3,814 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $1.7M · 2021: $205K · 2022: $21K · 2023: $57K · 2024: $278 · 2025: $3,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $60K · Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $60,384.98 |
| Food and Beverage | $660.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,683,834.00 | 2020 | |
| Medtronic, INC. | $286,486.45 | 2021-2025 | Ellipsys Vascular Access System |
| Sun Pharmaceutical Industries INC. | $204.78 | 2019-2024 | Cequa |
| Alcon Vision LLC | $166.36 | 2019-2024 | Clareon, Rocklatan |
| Abbvie INC. | $152.67 | 2023-2025 | |
| Rxsight INC | $149.82 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal) |
| Aerie Pharmaceuticals, INC. | $95.65 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $48.81 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $42.54 | 2019-2023 | |
| Harrow Eye, LLC | $39.39 | 2024-2025 | Vevye |
| Sight Sciences, INC. | $36.82 | 2019-2024 | Omni Surgical System |
| Allergan, INC. | $30.54 | 2020 | |
| Mallinckrodt Hospital Products INC. | $23.37 | 2024 | Acthar |
| Shire North American Group INC | $22.93 | 2019 | |
| Thea Pharma INC. | $19.25 | 2024 | Iyuzeh |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $16.59 | 2025 | Dextenza |
| Oyster Point Pharma, INC. | $16.01 | 2023 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.88 | 2019 | |
| Notal Vision, INC. | $2.59 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$725,120.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethnie Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.